Nemaura Medical, Inc. Common Stock
NMRD
NMRD was delisted on the 4th of January, 2024.
6 hedge funds and large institutions have $133K invested in Nemaura Medical, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 2 → 6 (+4)
37% more capital invested
Capital invested by funds: $97K → $133K (+$36K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
+$45.9K |
| 2 |
VF
Virtu Financial
New York
|
+$25.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$745 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.93K |
NMRD Hedge Fund Activity: Q3 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Nemaura Medical, Inc. Common Stock (NMRD) for Q3 2018, worth a combined $133K — up 37% from $97K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NMRD positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Prescott Group Capital Management, opening a new position worth an estimated $45.9K. The largest seller was Citadel Advisors, cutting an estimated $6.93K.
- 6 institutional investors held Nemaura Medical, Inc. Common Stock (NMRD) as of Q3 2018, up from 2 in Q2 2018.
- Funds reported $133K of Nemaura Medical, Inc. Common Stock stock for Q3 2018, up 37% quarter-over-quarter.
- 4 funds opened new Nemaura Medical, Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +4 holders.
- The largest Nemaura Medical, Inc. Common Stock buyer in Q3 2018 was Prescott Group Capital Management, an estimated $45.9K added.
- The largest Nemaura Medical, Inc. Common Stock seller in Q3 2018 was Citadel Advisors, an estimated $6.93K sold.
Based on aggregated 13F filings for Q3 2018.